Dr. Bansilal was an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai when he decided to seek out an alternative pathway to make an impact on patients’ lives.
This week, Dr. Ankur Kalra’s guest is Dr. Sameer Bansilal, Executive Director of U.S Medical Affairs of Cardiovascular and Renal at Bayer Pharmaceutical.
After years with the TIMI Study Group, Sameer decided to leave academic medicine to join the pharmaceutical industry. He was not alone with this career move; Dr. Jessica Mega had just joined Google Life Sciences and Dr. Laura Mauri became the Vice President of Medtronic. The image of being a physician at pharma was going through a change. In this informative and honest conversation, Sameer shares his personal journey and the transformation required in his new job. Ankur and Sameer talk about expanding our views and our pilgrimage as readers. Ankur asks Sameer about the positive and negative aspects of his current job. Sameer addresses some of the preconceptions related to physicians working for the industry and shares his advice for early and mid-career cardiologists who are considering this option.
Questions and comments can be sent to “podcast@radcliffe-group.com” and may be answered by Ankur in the next episode.
Brought to you by Edwards: www.edwardstavr.com
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
What drives Dr Nishtha Sodhi? What were the formative moments of Dr Sodhi’s career? What are the new frontiers of cardiology?
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
US Cardiology Review journal, has recently seen a 7-fold increase in female editorial board members in response to journal-based strategic initiatives and the stellar work of USC editorial board leadership, Ankur Kalra (Editor in Chief) and Bill Gogas (Deputy Editor in Chief), who were keen to drive this change. With thanks to Dr Anastasia Mihailidou’s tenure as a new board member and her suggested nominees, ten new female board members have recently joined US Cardiology Review’s editorial board.
In this episode, Mike opens up about his childhood in Stilwell, Oklahoma. Ankur and Mike discuss how the inductive quality of art can complement the deductive principles of science. Mike recalls earlier stages of his career and warns about the blinding effect of the ego-driven, competitive culture of cardiology. Ankur asks Mike about fatherhood and about his role as an educator.
What does it mean to be fearless as a medical professional? How can you protect yourself from the emotional toll of the profession? What is Mike’s advice to early career cardiologists?
Sponsored by Edwards.
During her interventional cardiology fellowship, Dr Baron became fascinated by the implementation of novel technologies. She earned her degree in Clinical Epidemiology and spent a year working at the FDA’s Device Evaluation unit.
In 2019 Dr Baron presented the results of her late-breaking trial, COAPT. Ankur invites Suzanne to discuss the economic analysis of the study and to give a short introduction to cost-effectiveness analysis. Suzanne provides an overview of the trial and they talk about the importance of understanding the value and benefits of new devices from both the patient and the health-economic point of viewpoint.
Together, Dr Kalra and Dr Darlington delve into the significance of assessing volume status in patients with heart failure, highlighting its continued relevance in 2024, including the availability of new diagnostic tools, including the Heart Failure Management System (HFMS).
This series is supported by ZOLL and is intended for Health Care Professionals.